News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics
Cyprumed and MSD sign a Non-Exclusive License and Option Agreement for the Development of Oral Peptide Therapeutics, potentially unlocking new opportunities in peptide therapeutics -
COMMUNIQUÉ DE PRESSE
EMERAM achieves success in challenging market environment: four investments and one exit in 2024, double-digit growth expected in 2025
EMERAM Capital Partners achieves success with four investments and one exit in 2024, predicts double-digit growth for 2025 amidst challenging market conditions -
-
-
-